nodes	percent_of_prediction	percent_of_DWPC	metapath
Ofloxacin—ABCC2—Mycophenolate mofetil—systemic scleroderma	0.129	0.227	CbGbCtD
Ofloxacin—SLC22A6—Captopril—systemic scleroderma	0.12	0.211	CbGbCtD
Ofloxacin—CYP1A2—Pentoxifylline—systemic scleroderma	0.0815	0.144	CbGbCtD
Ofloxacin—CYP1A2—Leflunomide—systemic scleroderma	0.0777	0.137	CbGbCtD
Ofloxacin—ABCC1—Methotrexate—systemic scleroderma	0.0698	0.123	CbGbCtD
Ofloxacin—ABCC2—Methotrexate—systemic scleroderma	0.0517	0.0911	CbGbCtD
Ofloxacin—SLC22A6—Methotrexate—systemic scleroderma	0.0378	0.0667	CbGbCtD
Ofloxacin—TOP2A—Methyltestosterone—Prednisone—systemic scleroderma	0.000627	1	CbGdCrCtD
Ofloxacin—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000124	0.000287	CcSEcCtD
Ofloxacin—Hypersensitivity—Azathioprine—systemic scleroderma	0.000124	0.000286	CcSEcCtD
Ofloxacin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000124	0.000286	CcSEcCtD
Ofloxacin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000286	CcSEcCtD
Ofloxacin—Insomnia—Lisinopril—systemic scleroderma	0.000123	0.000285	CcSEcCtD
Ofloxacin—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000123	0.000285	CcSEcCtD
Ofloxacin—Paraesthesia—Lisinopril—systemic scleroderma	0.000122	0.000283	CcSEcCtD
Ofloxacin—Vomiting—Captopril—systemic scleroderma	0.000122	0.000283	CcSEcCtD
Ofloxacin—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000282	CcSEcCtD
Ofloxacin—Dyspnoea—Lisinopril—systemic scleroderma	0.000122	0.000281	CcSEcCtD
Ofloxacin—Rash—Captopril—systemic scleroderma	0.000121	0.000281	CcSEcCtD
Ofloxacin—Dermatitis—Captopril—systemic scleroderma	0.000121	0.00028	CcSEcCtD
Ofloxacin—Somnolence—Lisinopril—systemic scleroderma	0.000121	0.00028	CcSEcCtD
Ofloxacin—Headache—Captopril—systemic scleroderma	0.000121	0.000279	CcSEcCtD
Ofloxacin—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000279	CcSEcCtD
Ofloxacin—Dyspepsia—Lisinopril—systemic scleroderma	0.00012	0.000278	CcSEcCtD
Ofloxacin—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00012	0.000277	CcSEcCtD
Ofloxacin—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00012	0.000277	CcSEcCtD
Ofloxacin—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000119	0.000276	CcSEcCtD
Ofloxacin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000119	0.000276	CcSEcCtD
Ofloxacin—Asthma—Methotrexate—systemic scleroderma	0.000119	0.000275	CcSEcCtD
Ofloxacin—Infection—Mycophenolate mofetil—systemic scleroderma	0.000119	0.000274	CcSEcCtD
Ofloxacin—Decreased appetite—Lisinopril—systemic scleroderma	0.000119	0.000274	CcSEcCtD
Ofloxacin—Eosinophilia—Methotrexate—systemic scleroderma	0.000118	0.000272	CcSEcCtD
Ofloxacin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000118	0.000272	CcSEcCtD
Ofloxacin—Fatigue—Lisinopril—systemic scleroderma	0.000118	0.000272	CcSEcCtD
Ofloxacin—Shock—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000272	CcSEcCtD
Ofloxacin—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000271	CcSEcCtD
Ofloxacin—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000117	0.00027	CcSEcCtD
Ofloxacin—Hypersensitivity—Leflunomide—systemic scleroderma	0.000117	0.00027	CcSEcCtD
Ofloxacin—Pancreatitis—Methotrexate—systemic scleroderma	0.000117	0.00027	CcSEcCtD
Ofloxacin—Pain—Lisinopril—systemic scleroderma	0.000117	0.00027	CcSEcCtD
Ofloxacin—Constipation—Lisinopril—systemic scleroderma	0.000117	0.00027	CcSEcCtD
Ofloxacin—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000117	0.00027	CcSEcCtD
Ofloxacin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000268	CcSEcCtD
Ofloxacin—Bradycardia—Prednisone—systemic scleroderma	0.000116	0.000268	CcSEcCtD
Ofloxacin—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000267	CcSEcCtD
Ofloxacin—Diarrhoea—Azathioprine—systemic scleroderma	0.000115	0.000266	CcSEcCtD
Ofloxacin—Haemoglobin—Prednisone—systemic scleroderma	0.000115	0.000265	CcSEcCtD
Ofloxacin—Nausea—Captopril—systemic scleroderma	0.000114	0.000264	CcSEcCtD
Ofloxacin—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000114	0.000264	CcSEcCtD
Ofloxacin—Haemorrhage—Prednisone—systemic scleroderma	0.000114	0.000264	CcSEcCtD
Ofloxacin—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000263	CcSEcCtD
Ofloxacin—Asthenia—Leflunomide—systemic scleroderma	0.000114	0.000263	CcSEcCtD
Ofloxacin—Hallucination—Prednisone—systemic scleroderma	0.000113	0.000262	CcSEcCtD
Ofloxacin—Pancytopenia—Methotrexate—systemic scleroderma	0.000113	0.000261	CcSEcCtD
Ofloxacin—Feeling abnormal—Lisinopril—systemic scleroderma	0.000112	0.00026	CcSEcCtD
Ofloxacin—Pruritus—Leflunomide—systemic scleroderma	0.000112	0.00026	CcSEcCtD
Ofloxacin—Connective tissue disorder—Prednisone—systemic scleroderma	0.000112	0.000259	CcSEcCtD
Ofloxacin—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000112	0.000258	CcSEcCtD
Ofloxacin—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000112	0.000258	CcSEcCtD
Ofloxacin—Dysuria—Methotrexate—systemic scleroderma	0.000111	0.000257	CcSEcCtD
Ofloxacin—Neutropenia—Methotrexate—systemic scleroderma	0.000111	0.000257	CcSEcCtD
Ofloxacin—Dizziness—Azathioprine—systemic scleroderma	0.000111	0.000257	CcSEcCtD
Ofloxacin—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000111	0.000256	CcSEcCtD
Ofloxacin—Erectile dysfunction—Methotrexate—systemic scleroderma	0.00011	0.000253	CcSEcCtD
Ofloxacin—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000252	CcSEcCtD
Ofloxacin—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000109	0.000251	CcSEcCtD
Ofloxacin—Asthenia—Mycophenolic acid—systemic scleroderma	0.000109	0.000251	CcSEcCtD
Ofloxacin—Diarrhoea—Leflunomide—systemic scleroderma	0.000109	0.000251	CcSEcCtD
Ofloxacin—Urticaria—Lisinopril—systemic scleroderma	0.000108	0.00025	CcSEcCtD
Ofloxacin—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000108	0.00025	CcSEcCtD
Ofloxacin—Body temperature increased—Lisinopril—systemic scleroderma	0.000108	0.000249	CcSEcCtD
Ofloxacin—Abdominal pain—Lisinopril—systemic scleroderma	0.000108	0.000249	CcSEcCtD
Ofloxacin—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000107	0.000248	CcSEcCtD
Ofloxacin—Pruritus—Mycophenolic acid—systemic scleroderma	0.000107	0.000248	CcSEcCtD
Ofloxacin—Vomiting—Azathioprine—systemic scleroderma	0.000107	0.000247	CcSEcCtD
Ofloxacin—Pneumonia—Methotrexate—systemic scleroderma	0.000107	0.000247	CcSEcCtD
Ofloxacin—Eye disorder—Prednisone—systemic scleroderma	0.000107	0.000246	CcSEcCtD
Ofloxacin—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000107	0.000246	CcSEcCtD
Ofloxacin—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000246	CcSEcCtD
Ofloxacin—Infestation NOS—Methotrexate—systemic scleroderma	0.000106	0.000245	CcSEcCtD
Ofloxacin—Infestation—Methotrexate—systemic scleroderma	0.000106	0.000245	CcSEcCtD
Ofloxacin—Drowsiness—Methotrexate—systemic scleroderma	0.000106	0.000245	CcSEcCtD
Ofloxacin—Rash—Azathioprine—systemic scleroderma	0.000106	0.000245	CcSEcCtD
Ofloxacin—Dermatitis—Azathioprine—systemic scleroderma	0.000106	0.000245	CcSEcCtD
Ofloxacin—Flushing—Prednisone—systemic scleroderma	0.000106	0.000245	CcSEcCtD
Ofloxacin—Headache—Azathioprine—systemic scleroderma	0.000105	0.000243	CcSEcCtD
Ofloxacin—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000105	0.000243	CcSEcCtD
Ofloxacin—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000243	CcSEcCtD
Ofloxacin—Dizziness—Leflunomide—systemic scleroderma	0.000105	0.000243	CcSEcCtD
Ofloxacin—Renal failure—Methotrexate—systemic scleroderma	0.000104	0.000241	CcSEcCtD
Ofloxacin—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000104	0.00024	CcSEcCtD
Ofloxacin—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000104	0.00024	CcSEcCtD
Ofloxacin—Stomatitis—Methotrexate—systemic scleroderma	0.000103	0.000239	CcSEcCtD
Ofloxacin—Angiopathy—Prednisone—systemic scleroderma	0.000103	0.000239	CcSEcCtD
Ofloxacin—Conjunctivitis—Methotrexate—systemic scleroderma	0.000103	0.000239	CcSEcCtD
Ofloxacin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000103	0.000239	CcSEcCtD
Ofloxacin—Immune system disorder—Prednisone—systemic scleroderma	0.000103	0.000238	CcSEcCtD
Ofloxacin—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000236	CcSEcCtD
Ofloxacin—Pain—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000236	CcSEcCtD
Ofloxacin—Arrhythmia—Prednisone—systemic scleroderma	0.000102	0.000235	CcSEcCtD
Ofloxacin—Haematuria—Methotrexate—systemic scleroderma	0.000101	0.000234	CcSEcCtD
Ofloxacin—Vomiting—Leflunomide—systemic scleroderma	0.000101	0.000233	CcSEcCtD
Ofloxacin—Alopecia—Prednisone—systemic scleroderma	0.000101	0.000233	CcSEcCtD
Ofloxacin—Hypersensitivity—Lisinopril—systemic scleroderma	0.0001	0.000232	CcSEcCtD
Ofloxacin—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.0001	0.000232	CcSEcCtD
Ofloxacin—Dizziness—Mycophenolic acid—systemic scleroderma	0.0001	0.000231	CcSEcCtD
Ofloxacin—Epistaxis—Methotrexate—systemic scleroderma	0.0001	0.000231	CcSEcCtD
Ofloxacin—Rash—Leflunomide—systemic scleroderma	0.0001	0.000231	CcSEcCtD
Ofloxacin—Dermatitis—Leflunomide—systemic scleroderma	0.0001	0.000231	CcSEcCtD
Ofloxacin—Mental disorder—Prednisone—systemic scleroderma	9.99e-05	0.000231	CcSEcCtD
Ofloxacin—Nausea—Azathioprine—systemic scleroderma	9.98e-05	0.000231	CcSEcCtD
Ofloxacin—Headache—Leflunomide—systemic scleroderma	9.94e-05	0.00023	CcSEcCtD
Ofloxacin—Erythema—Prednisone—systemic scleroderma	9.92e-05	0.000229	CcSEcCtD
Ofloxacin—Malnutrition—Prednisone—systemic scleroderma	9.92e-05	0.000229	CcSEcCtD
Ofloxacin—Agranulocytosis—Methotrexate—systemic scleroderma	9.9e-05	0.000229	CcSEcCtD
Ofloxacin—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	9.85e-05	0.000228	CcSEcCtD
Ofloxacin—Asthenia—Lisinopril—systemic scleroderma	9.78e-05	0.000226	CcSEcCtD
Ofloxacin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	9.77e-05	0.000226	CcSEcCtD
Ofloxacin—Pruritus—Lisinopril—systemic scleroderma	9.65e-05	0.000223	CcSEcCtD
Ofloxacin—Vomiting—Mycophenolic acid—systemic scleroderma	9.63e-05	0.000223	CcSEcCtD
Ofloxacin—Haemoglobin—Methotrexate—systemic scleroderma	9.58e-05	0.000221	CcSEcCtD
Ofloxacin—Rash—Mycophenolic acid—systemic scleroderma	9.55e-05	0.000221	CcSEcCtD
Ofloxacin—Dermatitis—Mycophenolic acid—systemic scleroderma	9.54e-05	0.000221	CcSEcCtD
Ofloxacin—Hepatitis—Methotrexate—systemic scleroderma	9.53e-05	0.00022	CcSEcCtD
Ofloxacin—Haemorrhage—Methotrexate—systemic scleroderma	9.53e-05	0.00022	CcSEcCtD
Ofloxacin—Urticaria—Mycophenolate mofetil—systemic scleroderma	9.49e-05	0.000219	CcSEcCtD
Ofloxacin—Headache—Mycophenolic acid—systemic scleroderma	9.48e-05	0.000219	CcSEcCtD
Ofloxacin—Pharyngitis—Methotrexate—systemic scleroderma	9.46e-05	0.000219	CcSEcCtD
Ofloxacin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	9.45e-05	0.000218	CcSEcCtD
Ofloxacin—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	9.45e-05	0.000218	CcSEcCtD
Ofloxacin—Nausea—Leflunomide—systemic scleroderma	9.43e-05	0.000218	CcSEcCtD
Ofloxacin—Urinary tract disorder—Methotrexate—systemic scleroderma	9.41e-05	0.000218	CcSEcCtD
Ofloxacin—Vision blurred—Prednisone—systemic scleroderma	9.35e-05	0.000216	CcSEcCtD
Ofloxacin—Urethral disorder—Methotrexate—systemic scleroderma	9.34e-05	0.000216	CcSEcCtD
Ofloxacin—Diarrhoea—Lisinopril—systemic scleroderma	9.33e-05	0.000216	CcSEcCtD
Ofloxacin—Ill-defined disorder—Prednisone—systemic scleroderma	9.21e-05	0.000213	CcSEcCtD
Ofloxacin—Visual impairment—Methotrexate—systemic scleroderma	9.18e-05	0.000212	CcSEcCtD
Ofloxacin—Anaemia—Prednisone—systemic scleroderma	9.17e-05	0.000212	CcSEcCtD
Ofloxacin—Agitation—Prednisone—systemic scleroderma	9.12e-05	0.000211	CcSEcCtD
Ofloxacin—Angioedema—Prednisone—systemic scleroderma	9.07e-05	0.00021	CcSEcCtD
Ofloxacin—Dizziness—Lisinopril—systemic scleroderma	9.02e-05	0.000209	CcSEcCtD
Ofloxacin—Erythema multiforme—Methotrexate—systemic scleroderma	9.01e-05	0.000208	CcSEcCtD
Ofloxacin—Nausea—Mycophenolic acid—systemic scleroderma	8.99e-05	0.000208	CcSEcCtD
Ofloxacin—Malaise—Prednisone—systemic scleroderma	8.95e-05	0.000207	CcSEcCtD
Ofloxacin—Vertigo—Prednisone—systemic scleroderma	8.92e-05	0.000206	CcSEcCtD
Ofloxacin—Eye disorder—Methotrexate—systemic scleroderma	8.9e-05	0.000206	CcSEcCtD
Ofloxacin—Syncope—Prednisone—systemic scleroderma	8.9e-05	0.000206	CcSEcCtD
Ofloxacin—Tinnitus—Methotrexate—systemic scleroderma	8.88e-05	0.000205	CcSEcCtD
Ofloxacin—Cardiac disorder—Methotrexate—systemic scleroderma	8.84e-05	0.000204	CcSEcCtD
Ofloxacin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	8.8e-05	0.000204	CcSEcCtD
Ofloxacin—Loss of consciousness—Prednisone—systemic scleroderma	8.72e-05	0.000202	CcSEcCtD
Ofloxacin—Vomiting—Lisinopril—systemic scleroderma	8.67e-05	0.0002	CcSEcCtD
Ofloxacin—Angiopathy—Methotrexate—systemic scleroderma	8.64e-05	0.0002	CcSEcCtD
Ofloxacin—Immune system disorder—Methotrexate—systemic scleroderma	8.61e-05	0.000199	CcSEcCtD
Ofloxacin—Rash—Lisinopril—systemic scleroderma	8.6e-05	0.000199	CcSEcCtD
Ofloxacin—Dermatitis—Lisinopril—systemic scleroderma	8.59e-05	0.000199	CcSEcCtD
Ofloxacin—Mediastinal disorder—Methotrexate—systemic scleroderma	8.59e-05	0.000199	CcSEcCtD
Ofloxacin—Asthenia—Mycophenolate mofetil—systemic scleroderma	8.57e-05	0.000198	CcSEcCtD
Ofloxacin—Hypertension—Prednisone—systemic scleroderma	8.57e-05	0.000198	CcSEcCtD
Ofloxacin—Chills—Methotrexate—systemic scleroderma	8.55e-05	0.000198	CcSEcCtD
Ofloxacin—Headache—Lisinopril—systemic scleroderma	8.54e-05	0.000198	CcSEcCtD
Ofloxacin—Pruritus—Mycophenolate mofetil—systemic scleroderma	8.45e-05	0.000195	CcSEcCtD
Ofloxacin—Myalgia—Prednisone—systemic scleroderma	8.45e-05	0.000195	CcSEcCtD
Ofloxacin—Arthralgia—Prednisone—systemic scleroderma	8.45e-05	0.000195	CcSEcCtD
Ofloxacin—Anxiety—Prednisone—systemic scleroderma	8.42e-05	0.000195	CcSEcCtD
Ofloxacin—Alopecia—Methotrexate—systemic scleroderma	8.42e-05	0.000195	CcSEcCtD
Ofloxacin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	8.39e-05	0.000194	CcSEcCtD
Ofloxacin—Discomfort—Prednisone—systemic scleroderma	8.35e-05	0.000193	CcSEcCtD
Ofloxacin—Mental disorder—Methotrexate—systemic scleroderma	8.35e-05	0.000193	CcSEcCtD
Ofloxacin—Malnutrition—Methotrexate—systemic scleroderma	8.29e-05	0.000192	CcSEcCtD
Ofloxacin—Erythema—Methotrexate—systemic scleroderma	8.29e-05	0.000192	CcSEcCtD
Ofloxacin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	8.17e-05	0.000189	CcSEcCtD
Ofloxacin—Dysgeusia—Methotrexate—systemic scleroderma	8.12e-05	0.000188	CcSEcCtD
Ofloxacin—Nausea—Lisinopril—systemic scleroderma	8.1e-05	0.000187	CcSEcCtD
Ofloxacin—Anaphylactic shock—Prednisone—systemic scleroderma	8.1e-05	0.000187	CcSEcCtD
Ofloxacin—Oedema—Prednisone—systemic scleroderma	8.1e-05	0.000187	CcSEcCtD
Ofloxacin—Infection—Prednisone—systemic scleroderma	8.05e-05	0.000186	CcSEcCtD
Ofloxacin—Back pain—Methotrexate—systemic scleroderma	8.02e-05	0.000185	CcSEcCtD
Ofloxacin—Shock—Prednisone—systemic scleroderma	7.97e-05	0.000184	CcSEcCtD
Ofloxacin—Nervous system disorder—Prednisone—systemic scleroderma	7.94e-05	0.000184	CcSEcCtD
Ofloxacin—Tachycardia—Prednisone—systemic scleroderma	7.9e-05	0.000183	CcSEcCtD
Ofloxacin—Dizziness—Mycophenolate mofetil—systemic scleroderma	7.9e-05	0.000183	CcSEcCtD
Ofloxacin—Skin disorder—Prednisone—systemic scleroderma	7.87e-05	0.000182	CcSEcCtD
Ofloxacin—Hyperhidrosis—Prednisone—systemic scleroderma	7.83e-05	0.000181	CcSEcCtD
Ofloxacin—Vision blurred—Methotrexate—systemic scleroderma	7.82e-05	0.000181	CcSEcCtD
Ofloxacin—Anorexia—Prednisone—systemic scleroderma	7.72e-05	0.000178	CcSEcCtD
Ofloxacin—Ill-defined disorder—Methotrexate—systemic scleroderma	7.69e-05	0.000178	CcSEcCtD
Ofloxacin—Anaemia—Methotrexate—systemic scleroderma	7.67e-05	0.000177	CcSEcCtD
Ofloxacin—Vomiting—Mycophenolate mofetil—systemic scleroderma	7.6e-05	0.000176	CcSEcCtD
Ofloxacin—Rash—Mycophenolate mofetil—systemic scleroderma	7.53e-05	0.000174	CcSEcCtD
Ofloxacin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	7.53e-05	0.000174	CcSEcCtD
Ofloxacin—Headache—Mycophenolate mofetil—systemic scleroderma	7.48e-05	0.000173	CcSEcCtD
Ofloxacin—Malaise—Methotrexate—systemic scleroderma	7.48e-05	0.000173	CcSEcCtD
Ofloxacin—Vertigo—Methotrexate—systemic scleroderma	7.45e-05	0.000172	CcSEcCtD
Ofloxacin—Leukopenia—Methotrexate—systemic scleroderma	7.42e-05	0.000172	CcSEcCtD
Ofloxacin—Musculoskeletal discomfort—Prednisone—systemic scleroderma	7.38e-05	0.000171	CcSEcCtD
Ofloxacin—Insomnia—Prednisone—systemic scleroderma	7.33e-05	0.000169	CcSEcCtD
Ofloxacin—Paraesthesia—Prednisone—systemic scleroderma	7.27e-05	0.000168	CcSEcCtD
Ofloxacin—Cough—Methotrexate—systemic scleroderma	7.24e-05	0.000167	CcSEcCtD
Ofloxacin—Dyspepsia—Prednisone—systemic scleroderma	7.13e-05	0.000165	CcSEcCtD
Ofloxacin—Nausea—Mycophenolate mofetil—systemic scleroderma	7.1e-05	0.000164	CcSEcCtD
Ofloxacin—Myalgia—Methotrexate—systemic scleroderma	7.06e-05	0.000163	CcSEcCtD
Ofloxacin—Chest pain—Methotrexate—systemic scleroderma	7.06e-05	0.000163	CcSEcCtD
Ofloxacin—Arthralgia—Methotrexate—systemic scleroderma	7.06e-05	0.000163	CcSEcCtD
Ofloxacin—Decreased appetite—Prednisone—systemic scleroderma	7.04e-05	0.000163	CcSEcCtD
Ofloxacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	7.01e-05	0.000162	CcSEcCtD
Ofloxacin—Fatigue—Prednisone—systemic scleroderma	6.98e-05	0.000161	CcSEcCtD
Ofloxacin—Discomfort—Methotrexate—systemic scleroderma	6.98e-05	0.000161	CcSEcCtD
Ofloxacin—Constipation—Prednisone—systemic scleroderma	6.93e-05	0.00016	CcSEcCtD
Ofloxacin—Confusional state—Methotrexate—systemic scleroderma	6.82e-05	0.000158	CcSEcCtD
Ofloxacin—Anaphylactic shock—Methotrexate—systemic scleroderma	6.77e-05	0.000157	CcSEcCtD
Ofloxacin—Infection—Methotrexate—systemic scleroderma	6.72e-05	0.000155	CcSEcCtD
Ofloxacin—Feeling abnormal—Prednisone—systemic scleroderma	6.67e-05	0.000154	CcSEcCtD
Ofloxacin—Nervous system disorder—Methotrexate—systemic scleroderma	6.64e-05	0.000153	CcSEcCtD
Ofloxacin—Thrombocytopenia—Methotrexate—systemic scleroderma	6.63e-05	0.000153	CcSEcCtD
Ofloxacin—Gastrointestinal pain—Prednisone—systemic scleroderma	6.62e-05	0.000153	CcSEcCtD
Ofloxacin—Skin disorder—Methotrexate—systemic scleroderma	6.57e-05	0.000152	CcSEcCtD
Ofloxacin—Hyperhidrosis—Methotrexate—systemic scleroderma	6.54e-05	0.000151	CcSEcCtD
Ofloxacin—Anorexia—Methotrexate—systemic scleroderma	6.45e-05	0.000149	CcSEcCtD
Ofloxacin—Urticaria—Prednisone—systemic scleroderma	6.43e-05	0.000149	CcSEcCtD
Ofloxacin—Abdominal pain—Prednisone—systemic scleroderma	6.4e-05	0.000148	CcSEcCtD
Ofloxacin—Body temperature increased—Prednisone—systemic scleroderma	6.4e-05	0.000148	CcSEcCtD
Ofloxacin—Hypotension—Methotrexate—systemic scleroderma	6.32e-05	0.000146	CcSEcCtD
Ofloxacin—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	6.17e-05	0.000143	CcSEcCtD
Ofloxacin—Insomnia—Methotrexate—systemic scleroderma	6.12e-05	0.000142	CcSEcCtD
Ofloxacin—Paraesthesia—Methotrexate—systemic scleroderma	6.08e-05	0.000141	CcSEcCtD
Ofloxacin—Dyspnoea—Methotrexate—systemic scleroderma	6.03e-05	0.00014	CcSEcCtD
Ofloxacin—Somnolence—Methotrexate—systemic scleroderma	6.02e-05	0.000139	CcSEcCtD
Ofloxacin—Hypersensitivity—Prednisone—systemic scleroderma	5.97e-05	0.000138	CcSEcCtD
Ofloxacin—Dyspepsia—Methotrexate—systemic scleroderma	5.96e-05	0.000138	CcSEcCtD
Ofloxacin—Decreased appetite—Methotrexate—systemic scleroderma	5.88e-05	0.000136	CcSEcCtD
Ofloxacin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	5.84e-05	0.000135	CcSEcCtD
Ofloxacin—Fatigue—Methotrexate—systemic scleroderma	5.84e-05	0.000135	CcSEcCtD
Ofloxacin—Asthenia—Prednisone—systemic scleroderma	5.81e-05	0.000134	CcSEcCtD
Ofloxacin—Pain—Methotrexate—systemic scleroderma	5.79e-05	0.000134	CcSEcCtD
Ofloxacin—Pruritus—Prednisone—systemic scleroderma	5.73e-05	0.000132	CcSEcCtD
Ofloxacin—Feeling abnormal—Methotrexate—systemic scleroderma	5.58e-05	0.000129	CcSEcCtD
Ofloxacin—Diarrhoea—Prednisone—systemic scleroderma	5.54e-05	0.000128	CcSEcCtD
Ofloxacin—Gastrointestinal pain—Methotrexate—systemic scleroderma	5.53e-05	0.000128	CcSEcCtD
Ofloxacin—Urticaria—Methotrexate—systemic scleroderma	5.38e-05	0.000124	CcSEcCtD
Ofloxacin—Dizziness—Prednisone—systemic scleroderma	5.36e-05	0.000124	CcSEcCtD
Ofloxacin—Body temperature increased—Methotrexate—systemic scleroderma	5.35e-05	0.000124	CcSEcCtD
Ofloxacin—Abdominal pain—Methotrexate—systemic scleroderma	5.35e-05	0.000124	CcSEcCtD
Ofloxacin—Vomiting—Prednisone—systemic scleroderma	5.15e-05	0.000119	CcSEcCtD
Ofloxacin—Rash—Prednisone—systemic scleroderma	5.11e-05	0.000118	CcSEcCtD
Ofloxacin—Dermatitis—Prednisone—systemic scleroderma	5.1e-05	0.000118	CcSEcCtD
Ofloxacin—Headache—Prednisone—systemic scleroderma	5.07e-05	0.000117	CcSEcCtD
Ofloxacin—Hypersensitivity—Methotrexate—systemic scleroderma	4.99e-05	0.000115	CcSEcCtD
Ofloxacin—Asthenia—Methotrexate—systemic scleroderma	4.86e-05	0.000112	CcSEcCtD
Ofloxacin—Nausea—Prednisone—systemic scleroderma	4.81e-05	0.000111	CcSEcCtD
Ofloxacin—Pruritus—Methotrexate—systemic scleroderma	4.79e-05	0.000111	CcSEcCtD
Ofloxacin—Diarrhoea—Methotrexate—systemic scleroderma	4.63e-05	0.000107	CcSEcCtD
Ofloxacin—Dizziness—Methotrexate—systemic scleroderma	4.48e-05	0.000103	CcSEcCtD
Ofloxacin—Vomiting—Methotrexate—systemic scleroderma	4.3e-05	9.95e-05	CcSEcCtD
Ofloxacin—Rash—Methotrexate—systemic scleroderma	4.27e-05	9.87e-05	CcSEcCtD
Ofloxacin—Dermatitis—Methotrexate—systemic scleroderma	4.26e-05	9.86e-05	CcSEcCtD
Ofloxacin—Headache—Methotrexate—systemic scleroderma	4.24e-05	9.8e-05	CcSEcCtD
Ofloxacin—Nausea—Methotrexate—systemic scleroderma	4.02e-05	9.3e-05	CcSEcCtD
